Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018

SAN DIEGO, March 8, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its fourth quarter and full year 2017 financial results will be released on Thursday, March 15, 2018, after the market close.  Pfenex management will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the financial results and provide a business update.

Pfenex logo (PRNewsFoto/Pfenex)

Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex to access the call.  A replay of the conference call will be available approximately one hour after the call until March 22, 2018.  To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10117964.  The conference call will also be available as a webcast.  To access the webcast link please log on to www.pfenex.com (http://www.pfenex.com).

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com), our investor relations website (http://pfenex.investorroom.com), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.  We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information.  Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.


SOURCE Pfenex Inc.

These press releases may also interest you

at 10:07
Buck, an integrated HR and benefits consulting, administration, and technology services firm, today announced that David Gillen, a Principal in Buck's Pittsburgh office, has been appointed to the Health Practice as Analytics Leader....

at 10:04
Cyber-attacks have become much more prevalent in the recent years and major corporations have faced some sort of breach. These breaches can compromise consumer information as well as directly impacting the company itself. Cyber-attacks are...

at 10:03
CTI BioPharma Corp. announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of the total number of...

at 10:02
Seal Software announced that it has released the Seal Financial Services Suite, the most comprehensive extraction and analytics platform for contractual data held by banks and financial services firms. The specialized platform utilizes artificial...

at 10:01
Periscope Data, the world's leading analytics platform for data professionals, has introduced its new Data Engine solution, powered by Amazon Web Services (AWS). Data Engine enables data-driven companies with complex pipelines or expanding data needs...

at 10:00
Motion Recruitment Partners, parent company of North American IT Staffing agencies - Jobspring Partners and Workbridge Associates, and global Recruitment Process Outsourcing (RPO) solution provider - Sevenstep, announced today that it has acquired...

News published on 8 march 2018 at 16:15 and distributed by: